Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-01-11 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于公司实际控制人增持计划实施进展的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a shareholding increase plan by the company's actual controller and CEO, Ding Lieming. It details the number of shares purchased, the dates, prices, and the percentage of total shares held before and after the increase. The content focuses on insider share transactions by a director and does not contain financial statements or broader financial results. It is not a full financial report, earnings release, or regulatory filing about financial performance. The document fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length and content confirm it is a detailed insider share transaction announcement rather than a brief notice or a report publication announcement.
2019-01-11 Chinese
股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company disclosing details about the pledge of shares by a major shareholder. It includes specifics such as the number of shares pledged, pledge start and end dates, pledgee information, and the proportion of shares pledged relative to total holdings. There is no financial performance data, no mention of earnings, no management discussion, no voting results, no legal proceedings, and no report publication. The content clearly relates to a shareholder's pledge of shares, which is a capital structure related update. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report but a substantive disclosure about share pledging.
2019-01-07 Chinese
中国国际金融股份有限公司关于公司2019年日常关联交易预计事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a special verification opinion issued by China International Capital Corporation Limited (the sponsor) regarding the 2019 expected daily related-party transactions of Betta Pharmaceuticals Co., Ltd. It includes detailed descriptions of related-party transactions, their amounts, pricing principles, and compliance with relevant regulations. The document is a verification or audit opinion on specific related-party transactions rather than a full annual report or audit report. It does not contain comprehensive financial statements or management discussion and analysis but focuses on the sponsor's verification opinion on related-party transactions for a specific year. The document length is 3512 characters, which is relatively short but contains substantive content rather than just an announcement. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or special verification opinions related to regulatory requirements, excluding full annual reports. FY 2019
2019-01-03 Chinese
关于BPI-23314药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company regarding the acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局). It details the acceptance notice numbers, the nature of the application (new drug application), and the implications for the company. The document is short (1410 characters) and serves as an official announcement of regulatory acceptance rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-01-03 Chinese
关于2019年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the expected daily related party transactions for the year 2019. It details the nature of the transactions, the parties involved, pricing principles, amounts, and includes independent directors' opinions and board meeting resolutions. The document is an announcement of anticipated related party transactions rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. The length is relatively short (3641 characters), and the content focuses on disclosure of related party transactions and approvals, which fits the profile of a Regulatory Filing (RNS) rather than a full Annual Report, Interim Report, or Audit Report. There is no indication that this is a report publication announcement or a certification letter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-12-28 Chinese
独立董事关于第二届董事会第三十次会议相关事项的事前认可和独立意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding a specific board meeting agenda item about anticipated related party transactions. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules, and provides independent opinions and approvals related to the board meeting. The document is short (1060 characters), contains no financial statements or detailed financial data, and is focused on governance and compliance matters related to board decisions. It is not an annual report, audit report, earnings release, or any financial report. It is not a voting result announcement or a proxy solicitation. It is a governance-related document expressing independent directors' opinions on a board matter. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2018-12-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.